Treatment of Peritonitis in Automated Peritoneal Dialysis
Secondary Peritonitis
About this trial
This is an interventional treatment trial for Secondary Peritonitis focused on measuring PERITONITIS, AUTOMATED PERITONEAL DIALYSIS, TREATMENT OF PERITONITIS
Eligibility Criteria
Inclusion Criteria:
- > 18 years in Automated Peritoneal Dialysis.
- Patients in the Hospital General 1, 10 and sub-zone 4 of Colima.
- Patients with diagnosis of peritonitis (abdominal pain, fever, vomiting, nausea, turbid fluid, cytologic with leukocytes >100 cells/mm3, polymorphonuclear >50%).
- Functional catheter.
- Signed informed consent of acceptance to participate in the study.
Exclusion Criteria:
- Patients allergic to vancomicyn.
- Patients allergic to ceftazidime.
- Patients with Intestinal perforation.
- Patients with abdominal cavity classified as unfit to PD.
Sites / Locations
- Hgz 10 Instituto Mexicano Del Seguro Social
- Hgsz 4 Instituto Mexicano Del Seguro Social
- Hgz 1 Instituto Mexicano Del Seguro Social
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Peritonitis treatment with one exchange in CAPD
Peritonitis treatment placed in APD
This group will receive peritonitis treatment with one exchange on Continuous Ambulatory Peritoneal Dialysis per day. The initial antibiotic scheme will be with ceftazidime (1500mg/day) and vancomycin (20mg/kg every 3 days) according to current management guidelines; adjusting the management according to the result of the culture, completing the antibiotic scheme for 14 to 21 days.
This group will receive peritonitis treatment placed in Automated Peritoneal Dialysis. The initial antibiotic scheme will be with ceftazidime (1500mg/day) and vancomycin (20mg/kg every 3 days); adjusting the management according to the result of the culture, completing the antibiotic scheme for 14 to 21 days.